Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
crispr
4
×
editas medicine
4
×
life sciences
national blog main
national top stories
new york blog main
4
×
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
fda
ipo
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
deals
eli lilly
indiana blog main
indiana top stories
nasdaq
novartis
startups
takeda pharmaceutical
abalos therapeutics
What
bio
roundup
ceo
medicine
acquisitions
announced
bails
benefiting
big
bosley's
bosley’s
boston
brand
bridge
bridgebio
bucks
capital
car
cas
collabs
coming
covid
crime
crispr
daniel
deal
departure
develop
diagnostics
drugs
editas
emerges
exit
firm
gilead
gilead’s
glimcher
grab
groundbreaking
guiding
Language
unset
Current search:
crispr
×
" new york blog main "
×
biotech
×
" editas medicine "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More